BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) closed Wednesday at $12.39 per share, down from $12.70 a day earlier. While BioCryst Pharmaceuticals Inc. has underperformed by -2.44%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BCRX rose by 0.16%, with highs and lows ranging from $19.99 to $7.61, whereas the simple moving average fell by -3.96% in the last 200 days.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
On November 02, 2022, Evercore ISI Upgraded BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) to Outperform. A report published by Oppenheimer on August 05, 2022, Downgraded its rating to ‘Perform’ for BCRX. Evercore ISI also Downgraded BCRX shares as ‘In-line’, setting a target price of $14 on the company’s shares in a report dated August 05, 2022. Barclays April 18, 2022d the rating to Equal Weight on April 18, 2022, and set its price target from $22 to $13. BofA Securities April 11, 2022d its ‘Buy’ rating to ‘Neutral’ for BCRX, as published in its report on April 11, 2022. Oppenheimer’s report from December 10, 2021 suggests a price prediction of $16 for BCRX shares, giving the stock a ‘Outperform’ rating. Jefferies also rated the stock as ‘Hold’.
Analysis of BioCryst Pharmaceuticals Inc. (BCRX)
Further, the quarter-over-quarter increase in sales is 84.90%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of BioCryst Pharmaceuticals Inc.’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of 106.40% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.90, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and BCRX is recording an average volume of 2.63M. On a monthly basis, the volatility of the stock is set at 5.44%, whereas on a weekly basis, it is put at 4.05%, with a loss of -3.88% over the past seven days. Furthermore, long-term investors anticipate a median target price of $17.60, showing growth from the present price of $12.39, which can serve as yet another indication of whether BCRX is worth investing in or should be passed over.
How Do You Analyze BioCryst Pharmaceuticals Inc. Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.20%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 81.20% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in BCRX shares?
The recent increase in stakes in BCRX appears to be a result of several institutional investors and hedge funds increasing their positions. The Vanguard Group, Inc.’s position in BCRX has increased by 0.18% in the first quarter. The company now owns 13,404,918 shares of the stock, with a value of $178.96 million, following the purchase of 23,863 additional shares during the last quarter. During the last quarter, the company dropped down 0 additional shares for a total stake of worth $169.69 million, bringing number of shares owned by the company to 12,710,818.
During the first quarter, BlackRock Fund Advisors subtracted a -185,744 position in BCRX. SSgA Funds Management, Inc. sold an additional -1.6 million shares in the last quarter, decreasing its holdings by -14.54%, now holding 9.4 million shares worth $125.55 million. At the end of the first quarter, Avoro Capital Advisor LLC increased its BCRX holdings by 39.23% and now holds 9.05 million BCRX shares valued at $120.82 million with the added 2.55 million shares during the period. BCRX shares are owned by institutional investors to the tune of 81.20% at present.